Peptides DB
Research-centric peptide and protocol reference hub

Pancragen (KEDW) record · updated 20h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 7 studiesJump to the evidenceCompare
What is Pancragen (KEDW) used for?

Pancragen (KEDW) is a synthetic tetrapeptide bioregulator studied for pancreatic endocrine support, glucose-insulin modulation, and longevity applications in preclinical and small human studies.

Primarily researched for · Metabolic & appetite

Development stage

where Pancragen (KEDW) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NamePancragen (KEDW)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassLongevity
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 11, 2026. How this works →
Research stats
Total studies7
Human / animal / cellular5 / 1 / 0
Highest trial phasePhase 4
Years covered2015–2025
Latest study20d ago
Publication history
20152025
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

7 rowsOpen in the library →
StudyTypeYearSummary depth
Pancreatic intraductal tubulopapillary neoplasm progression requiring completion pancreatectomy: A case report and literature review.
Finding5-year survival is over 70 % even with microinvasion.
Human2020Full text read0.70
A Community-Based Pancreatic Cancer Screening Study in High-Risk Individuals: Preliminary Efficacy and Safety Results.
Finding58.7% of participants had abnormal pancreatic findings.
Human2023Full text read0.80
Serial EUS-Guided FNA for the Surveillance of Pancreatic Cysts: A Study of Long-Term Performance of Tumor Markers.
Finding43 (36%) had a mutant KRAS on the index analysis.
Human2022Full text read0.80
EUS-guided fine needle aspiration-based clues to mistaken or uncertain identity: serous pancreatic cysts.
FindingHigh specificity cyst fluid biomarkers identified SCN in 25 of 27 (93%) cases.
Human2023Full text read0.80
Analytical Validation of Loss of Heterozygosity and Mutation Detection in Pancreatic Fine-Needle Aspirates by Capillary Electrophoresis and Sanger Sequencing.
TakeawayValidated molecular methods could improve diagnosis of pancreatic cysts, but clinical impact remains to be seen.
Human2024Full text read0.70
Challenges of early detection of pancreatic cancer.
TakeawayEarly detection of pancreatic cancer remains challenging, with significant work needed to optimize screening strategies for high-risk groups.
review2025Full text read0.80
[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys].
FindingNot reported in abstract.
Animal2015Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Pancragen (KEDW) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Pancragen (KEDW) is discussed should be drawn from it.